Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share

Report ID: GMI11141
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share

The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market positions. These efforts are aimed at enhancing their product and service offerings, expanding their geographic reach, and investing in advanced technologies. The market also witnesses the entry of new players, further intensifying the competitive landscape.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Companies

The company profile section includes both companies that have commercially available drugs in the market as well as those in the clinical phase of development. Prominent players operating in the market include:

Amgen Inc.
Apellis Pharmaceuticals, Inc.
AstraZeneca Plc
Children's National Hospital
F. Hoffmann-La Roche Ltd.
Memorial Sloan Kettering Cancer Center
Novartis AG
Pfizer, Inc.
Regeneron Pharmaceuticals Inc.
Teva Pharmaceuticals Industries Ltd.
UCLA Health
University of Rochester Medical Center

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The paroxysmal nocturnal hemoglobinuria treatment market was valued at USD 3.9 billion in 2023 and is expected to grow at 11.2% CAGR during 2024-2032 due to the rising prevalence of PNH.

The complement inhibitors segment in the market generated USD 1.4 billion in 2023 owing to the strong clinical results.

North America paroxysmal nocturnal hemoglobinuria treatment market held 46.6% in 2023 favored by the need for insurance coverage for high-cost drugs.

Amgen Inc., Apellis Pharmaceuticals, Inc., AstraZeneca Plc, Children's National Hospital, F. Hoffmann-La Roche Ltd., Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc., and Teva Pharmaceuticals Industries Ltd. among others.